#ADCBio2026 brings East Asia’s top experts together to advance ADC innovation and collaboration across biopharma, CMOs/CROs, regulators, and academia.
17 - 18 September 2026
Songdo Convensia, Incheon, South Korea
Co-located Events
Sponsors & Media Partners
Special thanks to our event partners, without whom we would not be able to provide this networking, learning, and collaborating platform.
Silver
Bronze
EXHIBITION & NETWORKING
.jpg)
Associate
2026 SPEAKERS
Doo Young Jung
Chief Executive Officer
PinotBio
South Korea
Chang Shou Gao
Chief Technology Officer
Allist Pharmaceuticals
China
Yo-Sup Rew
Chief Technology Officer
Intocell
South Korea
Wei Han Lee
Director CMC
OBI Pharma
Taiwan
Won Gyun Ahn
Associate Director
Qurient
South Korea
Chung Yi Wu
CEO
CHO Pharma
Taiwan
Dr. John Luk
CEO & Founder
ArbeleBio
United States
Wei Ting Sun
Director R&D
HoneyBear Bioscience
Taiwan
Akshaya Bansal
Executive Director, ADC Platforms
Hummingbird Bioscience
Singapore
Heon Chang Lim
Director, Formulation
Samsung Biologics
South Korea
Yi Yang
CEO & Founder
Glyco-therapy Biotech
China
Abbas Sahili
Chief Technology Officer
Singzyme
South Korea
Agenda At A Glance
CONFERENCE DAY 1 | 17 September 2026 |
|
.png)
|
|
|
Leadership Panel Discussion
Scaling Biologics & CGT in East Asia: Innovation, Manufacturing Challenges & Collaborative Strategies
|
|
| Morning Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Upstream Processing
Optimizing Cell Culture, Purification and Recovery
|
Discovery
Innovative Pathways in ADC Discovery: Unlocking Next-Gen Targeting Strategies
|
| Lunch, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Automation & Bioprocessing 4.0
Building Intelligent, Connected Facilities
|
Advancing Pre-Clinical Research
Bringing the Gap: From Pre-Clinical Insights to Clinical Success in ADC Development
|
| Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Quality & Analytics
Ensuring Precision and Compliance
|
ADC Biopharma Showcase
Pioneering Innovation and Excellence in Antibody-Drug Conjugates
|
| End of Conference Day 1 | |
CONFERENCE DAY 2 | 18 September 2026 |
|
|
|
|
|
Tech Transfer, Scale-Up & CMC Excellence
Bridging Development and Commercialisation
|
Leadership Panel Discussion
Redefining ADC Therapeutics: Addressing Toxicity, Enhancing Efficacy, and the Rise of Dual Payload Designs
|
| Morning Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
CAR-T & CAR-NK Therapies Case Studies
Next-Gen Cell Therapy & Preclinical Innovation
|
Scaling Up ADC Production
Overcoming Challenges in Bioconjugation and Purification
|
| Lunch, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Advancing Gene Therapy
Optimizing Vectors, Editing Technologies, and Smart Manufacturing
|
Optimizing ADC Target Selection and Engineering for Maximum Efficacy
Expanding the Next Wave of Precision Medicines
|
| Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Case Studies in Advanced Modalities
Peptides, Oligonucleotides, and Beyond
|
Advancing Payloads and Linker Technologies for Next-Generation ADCs
|
| End of Conference | |
CONFERENCE AGENDA
Day 1
Thursday, 17 September 2026
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
.png)
Leadership Panel Discussion: Scaling Biologics & ADC in East Asia:Innovation, Manufacturing Challenges & Collaborative Strategies
9:00
Leadership Panel Discussion: Scaling Biologics & ADC in East Asia:Innovation, Manufacturing Challenges & Collaborative Strategies
- Regional capacity expansion strategies and investment priorities
- Overcoming talent shortages, tech transfer challenges, and cost pressures
- Role of CDMOs, partnerships, and government collaboration
- Outlook for biologics and ADC manufacturing at scale
9:50
Arginine-Glutamate as Ideal Excipient for High Concentration Monoclonal Antibody Formulation.
- Need for higher dose of monoclonal antibodies(mAb) formulations
- Arginine-Glutamate a promising candidate to address concerns of aggregation, viscosity, liquid-liquid phase separation and longer storage
- Mechanism driving mAb stability in formulation containing Arginine-Glutamate
Hemasunder Reddy
Business Development Director, Pfanstiehl, Inc.
10:15
From Ambition to Execution: Why Scaling Biologics in East Asia Is Harder Than Anyone Admits
- Why most biologics scale-up failures are not technology problems, but execution, sequencing, and decision-timing failures
- The uncomfortable trade-offs manufacturing leaders must make between speed, cost, quality, and talent and why avoiding these decisions kills programs
- Where East Asian manufacturers systematically underestimate complexity: process transfer, organizational readiness, and inspection reality
- Hard lessons from scaling biologics and ADC programs that looked perfect on paper but struggled at GMP and commercial scale
10:40
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Discovery: Innovative Pathways in ADC Discovery: Unlocking Next-Gen Targeting Strategies
11:15
Case Studies in Glyco-engineering, Antibody-Drug Conjugates, and Next-generation Bioconjugation Technologies
(TBC)
Reserved for Dr. Chung Yi Wu
CEO, CHO Pharma, Taiwan
11:40
Reserved for Solution Provider
12:05
Next-Generation ADC Design: Engineering Dual-Payload and Novel Linker–Payload Systems for Enhanced Efficacy and Safety
(TBC)
Reserved for Dr. John Luk
CEO & Founder, Arbele Bio, Hong Kong/USA
12:30
Lunch Break, Exhibition Viewing & 1-1 Attendee Networking
Advancing Pre-Clinical Research: Bringing the Gap: From Pre-Clinical Insights to Clinical Success in ADC Development
1:45
TCE–ADC Combination Therapy in Hematologic Malignancies: The Need for Safer Payloads
Reserved for Wei Ting Sun
Director R&D, HoneyBear Bioscience, Taiwan
2:10
Reserved for Solution Provider
2:35
Formulation / Lyophilization Case Study for ADC Molecules: Challenges and Breakthrough
Heon Chang Lim
Director, Formulation, Samsung Biologics, South Korea
3:00
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
ADC Biopharma Showcase from East Asia Pioneering Innovation and Excellence in Antibody-Drug Conjugates
3:40
Advancing Clinical Progress of Next-Generation ADC Pipelines in East Asia
- Sharing latest clinical trial updates and milestones from ongoing ADC programmes in East Asia
- Highlighting early efficacy, safety, and translational data across solid tumour and haematology indications
- Discussing regulatory pathways and strategies to accelerate ADC approvals in Asia and global markets
4:05
Clinical Development Updates and Future Directions for Emerging ADC Therapies
- Presenting Phase I–III clinical progress and pipeline expansion strategies for novel ADC candidates
- Exploring patient selection, biomarker strategies, and combination therapy approaches in clinical studies
- Addressing key challenges in dose optimisation, toxicity management, and clinical differentiation
4:30
Translating ADC Innovation into Clinical Success Across East Asia
- Showcasing breakthrough clinical achievements and first-in-human data from East Asian biopharma companies
- Sharing lessons learned from ADC clinical development, manufacturing readiness, and global partnering efforts
- Evaluating the future landscape of ADC therapeutics including dual payloads, novel targets, and next-generation conjugation platforms
4:55
Chairman Closing Remarks
5:05
End of Conference Day 1
CONFERENCE AGENDA
Day 2
Friday, 18 September 2026
8:50
IMAPAC's Opening Address
8:55
Chairman's Opening Address
Leadership Panel Discussion: Redefining ADC Therapeutics: Addressing Toxicity, Enhancing Efficacy, and the Rise of Dual Payload Designs
9:00
Leadership Panel: Enhancing ADC Performance: Tackling Toxicity and Resistance
- Addressing dose-limiting toxicities in clinical settings
- Overcoming resistance through novel design approaches
- Role of dual payloads and combination strategies
9:50
Reserved for Solution Provider
10:05
Opening Keynote: Diving into ADCs Landscape in East Asia
(TBC)
Reserved for Dr. Xueming Qian
Founder & CEO, Transcenta Holding
10:30
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Exhibition Hall, Ballroom B
Scaling Up ADC Production: Overcoming Challenges in Bioconjugation and Purification
11:00
Purification and Analytical Strategies for High-Quality ADCs
(TBC)
Reserved for Hummingbird Bioscience
11:25
Reserved for Solution Provider
11:50
Bioconjugation Strategies for Next-Generation ADCs
(TBC)
- Site-specific conjugation techniques to improve homogeneity and efficacy
- Optimizing drug-to-antibody ratio (DAR) for safety and therapeutic index
- Case studies on novel linker technologies and payload innovations
Chang Shou Gao
Chief Technology Officer, Allist Pharmaceuticals, China
12:15
Lunch Break, Exhibition Viewing & 1-1 Attendee Networking
Optimizing ADC Target Selection and Engineering for Maximum Efficacy
1:45
Overcoming Resistance and Improving ADC Performance
Wei Han Lee
Director, CMC, OBI Pharma, South Korea
2:10
- Clinical differentiation: SGZ026 matches Enhertu-like efficacy with half the payload (DAR 3.9 vs 8), aiming for lower toxicity and COGS.
- Manufacturing edge: One-step, ~2h conjugation with >95% yield and minimal payload excess using GMP-ready enzymes.
- Better homogeneity & stability: Site-specific DAR control and a peptide-bond linkage to improve in-circulation stability and reduce payload shedding.
- Platform breadth: Applicable across all conjugates and formats (ADCs, RDCs, AOCs, proteins) with exclusive worldwide technology licenses plus in vivo validation (PDX/PK).
Abbas Sahili
Chief Technology Officer, Singzyme, Singapore
2:35
OHPASTM, PMTTM, and NexatecanTM Technologies for Enhanced ADC Efficacy and Safety
- OHPASTM linker design and PMTTM mechanism
- Proprietary NexatecanTM and iso-NexatecanTM TOP1 inhibitor payloads
- Next-generation ADC development enabled by IntoCell’s platform
Yo-Sup Rew
Chief Technology Officer, IntoCell, South Korea
3:00
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Premier Ballroom A
3:45
Combining Payload Selection, Linker Design and Site-specific Conjugation for Dual Payload ADC Development
- Importance of payload selection for the design of dual payload ADC - pharmacology and physicochemical properties perspective
- Exploitation of novel linkers to expand the applicable payload scope
- Improving stability of dual payload ADCs by applying site-specific conjugation
Doo Young Jung
CEO, PinotBio, South Korea
4:10
Beyond BsADCs: From Better Delivery to Checkmate Killing with Novel Proteasome Inhibitor Payload
- The ADC Evolution & The Lethality Gap
- The Next Wave: Overcoming Resistance
- Pioneering Novel Payloads (The QLi5 Platform)
Won Gyun Ahn
Associate Director, Qurient, South Korea
4:35
Optimizing Payload-Linker Integration for Superior ADC Performance
- Synergizing linker and payload design to maximize therapeutic index
- Impact of conjugation chemistry on payload delivery and efficacy
- Translational insights from preclinical optimization to clinical outcomes
5:00
Chairman Closing Remarks
5:05
End of Conference
By Profile
By Job Title
By Geography
5%
USA
3%
Europe
3%
Taiwan & India
3%
South East Asia
5%
Japan
5%
Singapore
68%
South Korea
3%
Other
5%
USA
3%
Europe
3%
Taiwan & India
3%
South East Asia
5%
Japan
5%
Singapore
68%
South Korea
3%
Other
Our Past Partners
.png)
